Bernard Taverne, Alice Desclaux, Papa Salif Sow

CHAPITRE II-2Lipodystrophies : prévalence, présentations cliniques et facteurs associésird-00718213, version 1 - 16 Jul 201240. Lichtenstein KA. Redefining lipodystrophy syndrome: risks andimpact on clinical decision making. J Acquir Immune Defic Syndr2005; 39: 395–400.41. Yao J, Yu W, Li T, Luo L, Lin Q, Tian J, Chang Y. The pilot studyof DXA assessment in chinese HIV-infected men with clinicallipodystrophy. J Clin Densitom. 2011 Jan-Mar;14(1):58-62.42. Palacios R, Galindo MJ, Arranz JA, Lozano F, Estrada V,Rivero A, et al. Cervical lipomatosis in HIV-infected patients: acase-control study. HIV Med. 2007 Jan;8(1):17-21.43. Rahim S, Ortiz O, Maslow M, Holzman R. A case-control studyof gynecomastia in HIV-1-infected patients receiving HAART. AIDSRead. 2004 Jan;14(1):23-4, 29-32, 35-40.44. Hadigan C., Meigs J.B., Wilson P.W.F., D’Agostino R.B., DavisB., Basgoz N., et al. Prediction of coronary heart disease risk inHIV-infected patients with fat redistribution. Clinical InfectiousDiseases, 2003, 36 : 909-916.45. Yususf S, Ounpuu S pour le groupe des investigateursINTERHEART. Effect of potentially modifiable risk factors associatedwith myocardial infarction in 52 countries (the INTERHEARTstudy): case-control study. Lancet 2004, 364: 937-52.46. Duval X., Baron G., Garelik D., Villes V., Dupre T., Leport C., etal. Living with HIV, antiretroviral treatment experience and tobaccosmoking: results from a multisite cross-sectional study Antivir.Ther. 2008 ; 13 : 389-397.47. Devlin R.J., Henry J.A. Clinical review: major consequences ofillicit drug consumption Crit. Care 2008 ; 12 : 202.48. Lewden C., May T., Rosenthal E., Burty C., Bonnet F., CostagliolaD., et al. Changes in causes of death among adults infectedby HIV between 2000 and 2005: The "Mortalite 2000 and 2005"surveys (ANRS EN19 and Mortavic) J. Acquir. Immune Defic.Syndr. 2008 ; 48 : 590-598.49. Mutimura E., Stewart A., Crowther N.J. Assessment of qualityof life in HAART-treated HIV-positive subjects with body fat redistributionin Rwanda. AIDS Research and Therapy, 2007, 4 : 19 (1-8).50. Crane HM, Grunfeld C, Harrington RD, Uldall KK, CiechanowskiPS, Kitahata MM. Lipoatrophy among HIV-infected patientsis associated with higher levels of depression than lipohypertrophy.HIV Med. 2008 Oct;9(9):780-6.51. Peterson S, Martins CR, Cofrancesco J Jr. Lipodystrophy in thepatient with HIV: social, psychological, and treatment considerations.Aesthet Surg J. 2008 Jul-Aug;28(4):443-51.52. Valantin M.A., Aubron-Olivier C., Ghosn J., Laglenne E.,Pauchard M., Schoen H., et al. Polylactic acid implants (New-Fill)to correct facial lipoatrophy in HIV-infected patients: results of theopen-label study VEGA AIDS 2003 ; 17 : 2471-2477.53. Falutz J., Allas S., Blot K., Potvin D., Kotler D., Somero M., etal. Metabolic effects of a growth hormone-releasing factor inpatients with HIV N. Engl. J. Med. 2007 ; 357 : 2359-2370.54. Levan P., Nguyen T.H., Lallemand F., Mazetier L., Mimoun M.,Rozenbaum W., et al. Correction of facial lipoatrophy in HIV-infectedpatients on highly active antiretroviral therapy by injection ofautologous fatty tissue AIDS 2002 ; 16 : 1985-1987.55. Behrens GM. Treatment options for lipodystrophy in HIV-positivepatients. Expert Opin Pharmacother. 2008 janv;9(1):39-52.56. Valantin MA, Katlama C. Anomalies de répartition du tissuadipeux dans l’infection à VIH. In Pr Christine Katlama, editeurs.VIH: complications et comorbidités. Paris: John Libbey Eorotext,2009. P. 1 – 16.57. Ribera E, Paradiñeiro JC, Curran A, Sauleda S, García-ArumíE, Castella E, et al. Improvements in subcutaneous fat, lipid profile,and parameters of mitochondrial toxicity in patients with peripherallipoatrophy when stavudine is switched to tenofovir (LIPOTESTstudy). HIV Clin Trials. 2008 Nov-Dec;9(6):407-17.58. Valantin MA, Lanoy E, Bentata M, Kalmykova O, BoutekadjirtA, Allavena C, et al. Recovery of fat following a switch to nucleosidereverse transcriptase inhibitor-sparing therapy in patients withlipoatrophy: results from the 96-week randomized ANRS 108NoNuke Trial. HIV Med. 2008 Oct;9(8):625-35.59. Domingo P, Sambeat MA, Pérez A, Ordoñez J, Rodriguez J,Vázquez G. Fat distribution and metabolic abnormalities in HIV-infectedpatients on first combination antiretroviral therapy includingstavudine or zidovudine: role of physical activity as a protectivefactor. Antivir Ther. 2003 Jun;8(3):223-31.60. Mutimura E., Crowther N.J., Cade T.W., Yarasheski K.E.,Stewart A. Exercise training reduces central adiposity and improvesmetabolic indices in HAART-treated HIVpositive subjects inRwanda : a randomized controlled trial. AIDS Research andTherapy, 2008, 24 : 15-23.61. Thoni G.J., Fedou C., Brun J.F., Fabre J., Renard E., ReynesJ., et al. Reduction of fat accumulation and lipid disorders byindividualized light aerobic training in human immunodeficiencyvirus infected patients with lipodystrophy and/or dyslipidemiaDiabetes Metab. 2002 ; 28 : 397-404.62. Lindegaard B., Hansen T., Hvid T., Van Hall G., Plomgaard P.,Ditlevsen S., et al. The effect of strength and endurance training oninsulin sensitivity and fat distribution in HIV-infected patients withlipodystrophy J. Clin. Endocrinol. Metab. 2008 ; 93 : 3860-3869.63. Van Griensven J, Zachariah R, Rasschaert F, Atté EF, Reid T.Weight evolution in HIV-1 infected women in Rwanda afterstavudine substitution due to lipoatrophy: comparison of zidovudinewith tenofovir/abacavir. Trans. R. Soc. Trop. Med. Hyg. 2009juin;103(6):613-619.76